NASDAQ: PRLD
Prelude Therapeutics Inc Stock Ownership - Who owns Prelude Therapeutics?

Insider buying vs selling

Have Prelude Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Jane HuangPresident CMO2025-04-043,355$0.68
$2.26kSell
Andrew CombsChief Chemistry Officer2025-03-25100,000$0.69
$69.30kBuy
Krishna VaddiCEO2025-03-25675,000$0.69
$467.77kBuy
Krishna VaddiCEO2025-03-2115,000$0.73
$10.97kBuy
Krishna VaddiCEO2025-03-205,416$0.73
$3.95kBuy
Krishna VaddiCEO2025-03-179,106$0.75
$6.83kBuy
Krishna VaddiCEO2025-03-1429,999$0.75
$22.62kBuy
Krishna VaddiCEO2025-03-1350,000$0.72
$35.80kBuy
Krishna VaddiCEO2025-03-1247,500$0.71
$33.73kBuy
Jane HuangPresident CMO2025-01-043,859$1.39
$5.36kSell

1 of 2

PRLD insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when PRLD insiders and whales buy or sell their stock.

PRLD Shareholders

What type of owners hold Prelude Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Orbimed Advisors LLC19.32%10,909,256$8.52MInstitution
Baker Bros Advisors LP17.93%10,123,824$7.91MInstitution
David P. Bonita17.32%9,776,491$7.64MInsider
Orbimed Advisors LLC17.32%9,776,491$7.64MInsider
Baker Bros Advisors LP16.39%9,252,951$7.23MInsider
Krishna Vaddi4.77%2,693,625$2.10MInsider
Boxer Capital Management LLC3.03%1,708,187$1.33MInstitution
Blackrock Inc1.89%1,069,773$835.49kInstitution
Price T Rowe Associates Inc1.82%1,029,199$803.80kInstitution
Vanguard Group Inc1.79%1,010,392$789.12kInstitution

1 of 3

PRLD vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
PRLD49.50%50.50%Net BuyingNet Buying
PEPG76.37%18.62%Net BuyingNet Buying
OTLK2.26%97.74%Net Buying
FBIO16.23%50.96%Net BuyingNet Buying
ARTV57.35%42.65%Net Buying

Prelude Therapeutics Stock Ownership FAQ

Who owns Prelude Therapeutics?

Prelude Therapeutics (NASDAQ: PRLD) is owned by 56.97% institutional shareholders, 58.11% Prelude Therapeutics insiders, and 0.00% retail investors. David P. Bonita is the largest individual Prelude Therapeutics shareholder, owning 9.78M shares representing 17.32% of the company. David P. Bonita's Prelude Therapeutics shares are currently valued at $8.63M.

If you're new to stock investing, here's how to buy Prelude Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.